Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000992146 | SCV001144180 | uncertain significance | not provided | 2019-06-17 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001002574 | SCV001160547 | uncertain significance | not specified | 2019-05-03 | criteria provided, single submitter | clinical testing | The HSPG2 c.662G>A; p.Arg221Gln variant (rs539990898), to our knowledge, is not reported in the medical literature or gene specific databases. This variant is found in the Finnish European population with an allele frequency of 0.036% (9/25098 alleles) in the Genome Aggregation Database. The arginine at codon 221 is weakly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is tolerated. Due to limited information, the clinical significance of the p.Arg221Gln variant is uncertain at this time. |
Labcorp Genetics |
RCV000992146 | SCV002166622 | uncertain significance | not provided | 2022-06-05 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 221 of the HSPG2 protein (p.Arg221Gln). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The glutamine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. ClinVar contains an entry for this variant (Variation ID: 804909). This variant has not been reported in the literature in individuals affected with HSPG2-related conditions. This variant is present in population databases (rs539990898, gnomAD 0.04%). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. |
Ambry Genetics | RCV002549780 | SCV003545306 | uncertain significance | Inborn genetic diseases | 2024-01-03 | criteria provided, single submitter | clinical testing | The c.662G>A (p.R221Q) alteration is located in exon 6 (coding exon 6) of the HSPG2 gene. This alteration results from a G to A substitution at nucleotide position 662, causing the arginine (R) at amino acid position 221 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV000992146 | SCV005373013 | uncertain significance | not provided | 2023-07-11 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |